News and Trends 11 Apr 2017 New Grant to Advance a Whole New Treatment Against Parkinson’s in the UK Mission Therapeutics has received a grant to support the development of a novel approach to treating Parkinson’s that is attracting top partners worldwide. Right on time for World Parkinson’s Day today, Mission Therapeutics has announced it has been awarded a research grant from the Michael J. Fox Foundation in the US. Named after its founder, the star of […] April 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 11 Apr 2017 Social Impact and Biotech: A Founder Revisits the Business Models A recent article published on Labiotech.eu provided some high-level insight into whether or not non-profit structures are suitable for biotechnology companies. In this article we dig a little deeper, and challenge some of the assumptions and hypotheses presented. Across the globe, there is a new movement of entrepreneurs emerging, which value making a positive impact with their […] April 11, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 10 Apr 2017 The Biggest European Medtech Exit of 2017 Just Happened The medtech company Symetis, specialized in heart valve replacements, today announced its acquisition by Boston Scientific in a hefty €411M ($435M) deal. Symetis is a Swiss medtech company and one of the key players on the European transcatheter aortic valve implantation (TAVI) market. After launching a promising €55M IPO on Euronext Paris in March, the company has now […] April 10, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 10 Apr 2017 Swiss-Danish Collaboration will use Synbio to Produce a B Vitamin Two startups in the fields of synthetic biology, Biosyntia and FGen, have struck a partnership to identify promising microbial strains. The objective is to find a strain that enables bioproduction of a B vitamin. The driving force of this new partnership between Biosyntia, Denmark, and ETH Zurich, and brands itself as a CRO for biologics […] April 10, 2017 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
Interview 10 Apr 2017 “Alzheimer’s is the Last Unclaimed Therapeutic Space,” says TauRx exec The Alzheimer’s field has been hit with a number of failures. I spoke to the COO/CBO of TauRx, whose alternative approach may yet succeed. Pharma is throwing all it can at the problem of Alzheimer’s Disease without any success to show for its efforts. Now the sixth leading cause of death across all age groups, […] April 10, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 8 Apr 2017 These Scientists are Turning the Human Brain into Art Neuroimaging artist duo DiMa takes the popular saying “beauty is inside” to another level by transforming complex visualizations of the brain into art. Diana Roettger and Matthew Rowe, who work together under the artistic name DiMa, are two imaging scientists that create art directly from scientific research. Originally from Germany and the UK, respectively, both hold […] April 8, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 7 Apr 2017 This Biotech Mining Probiotics to Treat the Skin has IPO’d in London SkinBioTherapeutics has raised £4,5M in its IPO on the London Stock Exchange to advance its probiotic technology for skin health applications. SkinBioTherapeutics, a spin-out from the University of Manchester, made its debut this week in AIM, the London Stock Exchange’s market for smaller growing companies. The £4,5M (€5.25M) raised will be used to continue the development […] April 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2017 This New Biotech counts with the Largest Antibiotic Resistance Database Curetis has launched Ares Genetics, a company that will use the biggest antibiotic resistance genetic database to advance the diagnose of infections. Ares Genetics, the new subsidiary of Curetis, will investigate the genetic foundation of antibiotic resistance to develop new approaches for the rapid diagnose of specific resistance in patients with infections, as well as tools to […] April 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2017 Evotec and Sanofi Hit the First Milestone for a Diabetes Cell Therapy Evotec and Sanofi have achieved preclinical proof-of-concept for a new beta cell therapy for diabetes, triggering a €3M milestone payment from Sanofi. In 2015, Sanofi and the German CRO Evotec partnered to jointly develop a beta cell replacement therapy for the treatment of diabetes in a deal that could reach more than €300M in potential milestone payments. […] April 6, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 6 Apr 2017 Fear & Loathing in GMOs: How do you change concerned minds? The house was packed to hear Joyce Tait of the Innogen Institute and Mark Lynas, an environmental writer, speak about smarter approaches to GM regulations. The second day of SynBioBeta yesterday started early, but fuelled by a passion for synthetic biology (on which a number of speakers commented), attendees packed into the lecture hall for a fireside chat on GMO regulation with Joyce […] April 6, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2017 Biotech Targeting Tau-Tangles in Neurodegeneration Initiates Clinical Trials Swiss Asceneuron has received regulatory approval to start its first Phase I trial of ASN120290, which is indicated for the treatment of dementia. Asceneuron was founded in 2012 as a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio. Its key asset ASN120290 is an inhibitor of the O-GlcNAcase enzyme and is indicated for the treatment of diseases associated […] April 6, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2017 UPDATE: Norwegian Stock Exchange hits Record Biotech IPO UPDATE (06/04/2017): BerGenBio has raised €43.55M, successfully beating a biotech record on the Norwegian stock exchange and setting its market cap at €135M. UPDATE (28/03/2017): BerGenBio has announced that the IPO could run up to €44M on Oslo Børs. It could become the Norway stock exchange’s biggest IPO in biotech, and indeed €44M would make it […] April 6, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email